NIH-funded research R01 grant

Investigating how a specific receptor affects multiple sclerosis progression

Official title: The role of TNFR2 in ameliorating progressive encephalomyelitis

Funded at University of Texas San Antonio · NIH-11004717 · Data updated 2026-11-12

This study is looking at how a specific brain receptor called TNFR2 might help protect and heal the nervous system in people with multiple sclerosis (MS), using a special mouse model to see how it works with different brain cells.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Texas San Antonio
NIH-funded
Lab location1 site (San Antonio, United States)
Project startFebruary 1, 2021
Project endDecember 31, 2025
Funding year2025
Award (this year)$337,715
NIH project number5R01NS117742-05
Project IDNIH-11004717 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with progressive multiple sclerosis who may benefit from novel treatment approaches targeting TNFR2.

Less likely to help

Patients with non-progressive forms of multiple sclerosis or other unrelated neurological conditions may not receive any benefit from this research.

What this research studies

This research focuses on understanding the role of the TNFR2 receptor in the progression of multiple sclerosis (MS). It explores how TNFR2 can potentially protect the central nervous system and promote repair mechanisms in patients with MS. By using a specialized mouse model that mimics human MS, the researchers aim to uncover the beneficial effects of TNFR2 expressed by astrocytes, a type of brain cell. The study will involve examining the interactions between different cell types in the brain and how they contribute to either disease progression or recovery.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that harness the protective effects of TNFR2 to slow down or reverse the progression of multiple sclerosis.

How similar studies have gone: Previous research has indicated that targeting TNF pathways can have both beneficial and detrimental effects in autoimmune diseases, suggesting that this approach may yield novel insights into MS treatment.

Where this research is happening

  • University of Texas San Antonio
    San Antonio, United States
    Active

Researchers

  • Principal investigator: Forsthuber, Thomas G. — University of Texas San Antonio
  • Study coordinator: Forsthuber, Thomas G.

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.